Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) – Pipeline Review, H2 2017’, provides in depth analysis on Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)

The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Eli Lilly and Co

Enumeral Biomedical Holdings Inc

Incyte Corp

Interprotein Corp

Jounce Therapeutics Inc

Merus NV

Novartis AG

Sorrento Therapeutics Inc

Sutro Biopharma Inc

Tesaro Inc

Trellis Bioscience Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview 7

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development 19

Aurigene Discovery Technologies Ltd 19

BeiGene Ltd 19

Eli Lilly and Co 20

Enumeral Biomedical Holdings Inc 20

Incyte Corp 20

Interprotein Corp 21

Jounce Therapeutics Inc 21

Merus NV 22

Novartis AG 22

Sorrento Therapeutics Inc 23

Sutro Biopharma Inc 23

Tesaro Inc 24

Trellis Bioscience Inc 24

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles 25

BGBA-425 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Bispecific Monoclonal Antibody to Inhibit TIM3 for Oncology - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CA-170 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CA-327 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ENUM-005 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

IMM-1802 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LY-3321367 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MCLA-134 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MGB-453 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Monoclonal Antibodies 3 to Inhibit TIM3 for Oncology - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Monoclonal Antibody to Inhibit TIM3 for Oncology - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

STI-600 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

TRL-6061 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

TSR-022 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products 44

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones 45

Featured News & Press Releases 45

Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 45

Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress 46

May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting 46

Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference 46

Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist 47

Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment 48

Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing 49

Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints 49

Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA 49

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting 50

Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA Program at AACR-NCI-EORTC International Conference 50

Nov 02, 2015: Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference 50

Oct 19, 2015: Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 19

Pipeline by BeiGene Ltd, H2 2017 19

Pipeline by Eli Lilly and Co, H2 2017 20

Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 20

Pipeline by Incyte Corp, H2 2017 21

Pipeline by Interprotein Corp, H2 2017 21

Pipeline by Jounce Therapeutics Inc, H2 2017 22

Pipeline by Merus NV, H2 2017 22

Pipeline by Novartis AG, H2 2017 23

Pipeline by Sorrento Therapeutics Inc, H2 2017 23

Pipeline by Sutro Biopharma Inc, H2 2017 24

Pipeline by Tesaro Inc, H2 2017 24

Pipeline by Trellis Bioscience Inc, H2 2017 24

Dormant Projects, H2 2017 44

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports